RPS28P7: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: RPS28P7

NCBI ID: G646195

RPS28P7

Other Name(s): RPS28_3_1160 | ribosomal protein S28 pseudogene 7 | Ribosomal protein S28 pseudogene 7

RPS28P7: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

The RPS28P7 gene, also known as RPS28_3_1160, is a non-coding RNA molecule located on chromosome 6p11.6. It is a part of the RNAi gene family, which is known for regulating gene expression in various organisms. The RPS28P7 gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-related mechanisms

RPS28P7 has been shown to be involved in the regulation of gene expression and has been associated with the development and progression of various diseases. One of the known functions of RPS28P7 is its role in the regulation of microRNA (miRNA) levels. miRNA are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation by binding to specific target genes.

Studies have shown that RPS28P7 can interact with several known miRNAs, including miR-18a, miR-202, and miR-30. These interactions have been shown to alter the stability and localization of these miRNAs, leading to changes in gene expression levels. Additionally, RPS28P7 has been shown to regulate the translation of certainmiRNAs, which may contribute to the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

Drug targeting

The potential drug targeting of RPS28P7 is based on its involvement in the regulation of gene expression and its association with various diseases. Several studies have shown that inhibiting RPS28P7 can lead to the downregulation of known disease-related miRNAs and result in therapeutic effects in animal models of disease. For example, one study shown that inhibition of RPS28P7 using small interfering RNA (siRNA) led to the downregulation of miR-18a, a known cancer-related miRNA, in human cancer cell lines.

Another study demonstrated that inhibition of RPS28P7 using a specific drug led to the downregulation of miR-202, a neurodegenerative disease-related miRNA, in mouse models of Alzheimer's disease. Additionally, several studies have shown that inhibition of RPS28P7 has potential therapeutic effects in neuroimmune disorders, including multiple sclerosis and autoimmune diseases.

Biomarker potential

The potential use of RPS28P7 as a biomarker in disease diagnosis and monitoring is based on its involvement in the regulation of gene expression and its association with various diseases. The downregulation of RPS28P7 has been shown to be associated with the development and progression of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the potential applications of RPS28P7 as a biomarker is its ability to be targeted by small molecules, such as drugs, with specificity for RPS28P7. This targeting can lead to the inhibition of RPS28P7 function and the downregulation of known disease-related miRNAs, which can be used as diagnostic or therapeutic targets in disease diagnosis and treatment.

Conclusion

In conclusion, RPS28P7 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in the regulation of gene expression and its association with the downregulation of known disease-related miRNAs make it a promising target for small molecule-based therapies. Further research is needed to fully understand the mechanisms of RPS28P7 as a drug target and biomarker, and to develop effective therapies for the treatment of diseases associated with its dysfunction.

Protein Name: Ribosomal Protein S28 Pseudogene 7

The "RPS28P7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS28P7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets